{"title":"Formulation and evaluation of controlled porosity osmotic pump for oral delivery of ketorolac.","authors":"Fatima Sanjeri Dasankoppa, Mahesh Ningangowdar, Hasanpasha Sholapur","doi":"10.4103/0976-0105.109398","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The osmotic drug delivery systems suitable for oral administration typically consist of a compressed tablet core that is coated with a semipermeable membrane that has an orifice drilled on it by means of a laser beam or mechanical drill. Ketorolac is a nonsteroidal agent with powerful analgesic. Oral bioavailability of ketorolac was reported to be 90% with very low hepatic first-pass elimination; the biological half-life of 4-6 hours requires frequent administration to maintain the therapeutic effect.</p><p><strong>Aim: </strong>The aim of the current study was to design a controlled porosity osmotic pump (CPOP)based drug delivery system for controlled release of an NSAID agent, ketorolac tromethamine, which is expected to improve patient compliance due to reduced frequency; it also eliminates the need for complicated and expensive laser drilling and maintain continuous therapeutic concentration.</p><p><strong>Design: </strong>The CPOP was designed containing pore-forming water-soluble additives in the coating membrane, which after coming in contact with water, dissolve, resulting in an in situ formation of a micro porous structure.</p><p><strong>Materials and methods: </strong>The effect of different formulation variables, namely level of pore former (PVP), plasticizer (dibutyl phthalate) in the membrane, and membrane weight gain were studied.</p><p><strong>Results and conclusion: </strong>Drug release was inversely proportional to the membrane weight but directly related to the initial concentration of pore former (PVP) in the membrane. Drug release was independent of pH and agitational intensity, but dependent on the osmotic pressure of the release media. Based on the in vitro dissolution profile, formulation F3C1 (containing 0.5 g PVP and 1 g dibutyl phthalate in coating membrane) exhibited Peppas kinetic with Fickian diffusion-controlled release mechanism with a drug release of 93.67% in 12 hours and hence it was selected as optimized formulation. SEM studies showed the formation of pores in the membrane. The formulations were stable after 3 months of accelerated stability studies. CPOP was designed for effective administration of drugs for prolonged period of time.</p>","PeriodicalId":15046,"journal":{"name":"Journal of Basic and Clinical Pharmacy","volume":"4 1","pages":"2-9"},"PeriodicalIF":0.0000,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4103/0976-0105.109398","citationCount":"25","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Basic and Clinical Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/0976-0105.109398","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 25
Abstract
Background: The osmotic drug delivery systems suitable for oral administration typically consist of a compressed tablet core that is coated with a semipermeable membrane that has an orifice drilled on it by means of a laser beam or mechanical drill. Ketorolac is a nonsteroidal agent with powerful analgesic. Oral bioavailability of ketorolac was reported to be 90% with very low hepatic first-pass elimination; the biological half-life of 4-6 hours requires frequent administration to maintain the therapeutic effect.
Aim: The aim of the current study was to design a controlled porosity osmotic pump (CPOP)based drug delivery system for controlled release of an NSAID agent, ketorolac tromethamine, which is expected to improve patient compliance due to reduced frequency; it also eliminates the need for complicated and expensive laser drilling and maintain continuous therapeutic concentration.
Design: The CPOP was designed containing pore-forming water-soluble additives in the coating membrane, which after coming in contact with water, dissolve, resulting in an in situ formation of a micro porous structure.
Materials and methods: The effect of different formulation variables, namely level of pore former (PVP), plasticizer (dibutyl phthalate) in the membrane, and membrane weight gain were studied.
Results and conclusion: Drug release was inversely proportional to the membrane weight but directly related to the initial concentration of pore former (PVP) in the membrane. Drug release was independent of pH and agitational intensity, but dependent on the osmotic pressure of the release media. Based on the in vitro dissolution profile, formulation F3C1 (containing 0.5 g PVP and 1 g dibutyl phthalate in coating membrane) exhibited Peppas kinetic with Fickian diffusion-controlled release mechanism with a drug release of 93.67% in 12 hours and hence it was selected as optimized formulation. SEM studies showed the formation of pores in the membrane. The formulations were stable after 3 months of accelerated stability studies. CPOP was designed for effective administration of drugs for prolonged period of time.
背景:适用于口服给药的渗透给药系统通常由压缩的片剂芯组成,片剂芯涂有半透膜,半透膜上有通过激光束或机械钻在其上钻孔的孔。酮咯酸是一种非甾体类强效镇痛药。据报道,酮咯酸的口服生物利用度为90%,肝脏首过消除率极低;生物半衰期为4-6小时,需要经常给药以维持治疗效果。目的:本研究的目的是设计一种基于可控孔隙渗透泵(CPOP)的非甾体抗炎药酮咯酸三甲胺的控释给药系统,由于频率降低,该系统有望提高患者的依从性;它还消除了复杂和昂贵的激光钻孔的需要,并保持持续的治疗浓度。设计:CPOP的涂层膜中含有成孔水溶性添加剂,该添加剂与水接触后溶解,在原位形成微孔结构。材料与方法:研究了不同配方变量对膜中孔隙成形剂(PVP)、增塑剂(邻苯二甲酸二丁酯)含量、膜增重的影响。结果与结论:药物释放量与膜质量成反比,而与膜中孔隙原(PVP)的初始浓度直接相关。药物释放不受pH值和搅拌强度的影响,而取决于释放介质的渗透压。基于体外溶出度分析,处方F3C1(包膜中含有0.5 g PVP和1 g邻苯二甲酸二丁酯)具有Peppas动力学和Fickian扩散控制释放机制,12 h释药率为93.67%,优选处方F3C1。扫描电镜研究表明,膜上形成了孔隙。经过3个月的加速稳定性研究,配方是稳定的。CPOP是为长期有效给药而设计的。